Invitrogen™ mMESSAGE mMACHINE™ T7 mRNA Kit with CleanCap™ Reagent AG
Simplify the in vitro synthesis and scale-up of potent mRNA with the third generation, proven CleanCap capping technology for increased translatability in vivo.
Receive your quote directly from the manufacturer.
The mMESSAGE mMACHINE T7 mRNA Kit with CleanCap Reagent AG contains all the reagents and buffers necessary for in vitro synthesis of large amounts of mRNA with the naturally occurring Cap 1 structure for increased translatability in vivo compared to legacy capping methods such as the use of anti-reverse capping analog (ARCA). Utilization of the CleanCap Reagent AG ensures superior results relative to older capping technologies and greater protein production. Each standard 20-μL reaction yields a minimum of 100 μg of Cap 1-containing mRNA, while the scaled-up protocol yields up to 1 mg of mRNA. This kit is suitable for full- or partially-modified-nucleotide substitution to generate modified mRNA.
Key features:
- Contains proven CleanCap capping technology
- Optimized to achieve high mRNA yields (>5 mg/mL)
- Produces mRNA that is over 95% capped
- Optimized for production of mRNA from 0.9–10 kb templates
- Minimum yields of 100 μg per reaction, up to 150 μg per reaction (see figure below)
- Allows use of modified nucleotides, full- or partial-modified substitution
- Includes linearized 0.9 kb GFP control template, yields ≥100 μg mRNA
- Made up of high quality TheraPure reagents to enable transition from RUO to GMP
